Is it possible to cure myeloma without allogeneic transplantation?

Transfus Apher Sci. 2016 Feb;54(1):63-70. doi: 10.1016/j.transci.2016.01.015. Epub 2016 Jan 21.

Abstract

During the last decades, a better understanding of the biology of multiple myeloma (MM) has led to the application of novel treatment strategies for MM patients. The new anti-myeloma regimens produce higher incidence of durable and of better quality responses and they improve overall survival, challenging the dogma of incurable disease, outside the context of allogeneic transplantation. This review presents all these strategies that aim to cure MM, including continuous treatment i.e. induction, consolidation and maintenance, treatment of asymptomatic MM and monitoring minimal residual disease using modern techniques, such as multi-parameter flow cytometry, molecular assays and advanced imaging.

Keywords: Allogeneic; Bortezomib; Immunomodulatory drugs; Multiple myeloma; Translantation.

Publication types

  • Review

MeSH terms

  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Multiple Myeloma / therapy*
  • Neoplasm, Residual / pathology
  • Transplantation, Homologous